Squarepoint’s Sarepta Therapeutics SRPT Stock Holding History

Squarepoint’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-20,300	Closed	-$437K	–	4939
2025 Q4	$437K	Sell	20,300 -24,600	-55%	-$518K	﹤0.01%	3316
2025 Q3	$865K	Buy	44,900 +22,500	+100%	+$401K	﹤0.01%	2805
2025 Q2	$383K	Sell	22,400 -32,300	-59%	-$1.38M	﹤0.01%	3503
2025 Q1	$3.49M	Buy	54,700 +30,800	+129%	+$3.24M	﹤0.01%	1674
2024 Q4	$2.91M	Buy	23,900 +17,400	+268%	+$2.13M	﹤0.01%	2079
2024 Q3	$812K	Buy	6,500 +5,200	+400%	+$719K	﹤0.01%	2762
2024 Q2	$205K	Sell	1,300 -16,600	-93%	-$2.13M	﹤0.01%	3644
2024 Q1	$2.32M	Buy	+17,900	New	+$2.19M	﹤0.01%	2002

Other funds holding SRPT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Squarepoint's SRPT Position: Q1 2026 in Review

Squarepoint increased its Sarepta Therapeutics (SRPT) stake by 192% in Q1 2026, buying an estimated $1.89M and bringing the position to 148,802 shares worth $3.24M. The position accounts for ﹤0.01% of the portfolio, ranked #1827.

Squarepoint first reported a position in SRPT in Q4 2016 and has held it in 32 quarters since. The position peaked at $26.8M in Q4 2022. 339 funds tracked by Wall St. Rank hold SRPT as of Q1 2026.

Squarepoint held 148,802 shares of Sarepta Therapeutics worth $3.24M as of Q1 2026.
Squarepoint bought 97,866 Sarepta Therapeutics shares in Q1 2026, an estimated $1.89M.
Sarepta Therapeutics made up ﹤0.01% of Squarepoint's portfolio in Q1 2026, its #1827 holding.
Squarepoint first reported a position in Sarepta Therapeutics in Q4 2016 and has held it in 32 quarters since.
Squarepoint's Sarepta Therapeutics position peaked at $26.8M in Q4 2022.
339 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.